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Abstract
Background: Reprogrammed metabolism is a new hallmark of cancer. In many types of cancer, most of the genes
in the glycolytic pathway are overexpressed, reflecting an essential shift of metabolism during cancer development.
The reprogrammed metabolism contributes to cancer development in multiple ways, from supplying the elevated
energy requirement to creating a microenvironment suitable for tumor growth and suppressing the human
immune surveillance system.
Method: In this study, a functional proteomics top-down approach was used to systematically monitor metabolic
enzyme activities in resolved serum proteins produced by a modified 2-D gel separation and subsequent Protein
Elution Plate, a method collectively called PEP.
Results: We found that the enrichment of low abundance proteins with a bead based product called AlbuVoid™, is
important to increase the number of observable features and to increase the level of signal achievable from the assay
used. From our methods, significant metabolic enzyme activities were detected in both normal and lung cancer
patient sera in many fractions after the elution of the 2-D gel separated proteins to the Protein Elution Plate
(PEP). Eighteen fractions with the most dramatic metabolic enzyme activity difference between the normal and
lung cancer patient sera were submitted for mass spectrometry protein identification. Proteins from the glycolytic
metabolic pathway, such as GAPDH along with other proteins not previously annotated to the glycolytic pathway
were identified. Further verification with commercially purified GAPDH showed that the addition of purified
GAPDH to the metabolic enzyme assay system employed enhanced the enzyme activity, demonstrating that proteins
identified from the PEP technology and mass spectrometry could be further verified with biological assay.
Conclusion: This study identified several potential functional enzyme biomarkers from lung cancer patient serum,
it provides an alternative and complementary approach to sequence annotation for the discovery of biomarkers
in human diseases.
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Background
Lung cancer is one of the most common malignancies
and the leading cause in cancer-related fatality. In the
U.S. alone, more than 210,000 new lung cancer cases are
diagnosed with more than 170,000 deaths resulting from
this disease each year. Lung cancer is the 5th leading
cause of death worldwide, there were 1.5 million lung
cancer deaths in 2010, an increase of 48 % in the past
20 years [32]. Usually symptoms of lung cancer do not
appear until the disease is already in an advanced, non-
curable stage. Most patients present with advanced dis-
ease and 5-year survival rates are poor, ranging from less
than 10 % in China to 13–16 % in Europe and the US
[32]. Even when symptoms of lung cancer do appear,
many people may mistake them for other problems,
such as an infection or long-term effects from smoking,
delaying the disease diagnosis. Current practice on the
diagnosis of common cancers relies heavily on imaging
technologies such as CT scans for lung cancer, mammo-
grams for breast cancer and pelvic ultrasounds for ovar-
ian cancer. While advances in imaging technology have
allowed more sensitive detection of small lesions, these
advances have also led to an increase in false positive
findings and invasive procedures to make a definitive
diagnosis. For example in lung cancer; the CT scanners
have led to the detection of large numbers of small pul-
monary nodules. The frequency of detecting noncalcified
nodules on a single CT varies from 5 to 60 % in a lung
cancer screening population [12]. Given the high prob-
ability of false positive findings associated with CT
screening, there is a substantial need for additional non-
invasive modalities to discriminate between benign and
malignant nodules. There are similar challenges in im-
aging based screening for other malignancies and a sub-
sequent need for complementary diagnostic tests.
Blood based biomarkers have potential in cancer screen-
ing and their role could extend further from general popu-
lation risk assessment to treatment response evaluation
and recurrence monitoring. The rich content of di-
verse cellular and molecular elements in blood, which
provide information about the health status of an indi-
vidual, make it an ideal compartment to develop non-
invasive diagnostics for cancer [42]. However, despite
a large literature collection related to biomarkers for
common cancers, blood based diagnostic tests that in-
form about the presence of cancer at an early stage
and predict treatment response have been difficult to
develop [24, 47]. Protein markers currently in clinical
use, which include CA125 (cancer antigen 125) for
ovarian cancer, CA199 (carbohydrate antigen 199) for
pancreatic cancer, CEA (carcino embryonic antigen)
for colon cancer and PSA (prostate specific antigen)
for prostate cancer, have limitations with respect to
their use for screening owing to low sensitivity and
specificity in early stages and inability to distinguish
aggressive from indolent tumors [11]. Other common
cancers, notably breast and lung cancer, lack established
biomarkers with demonstrated clinical utility in a screen-
ing setting. Thus, there is a need for biomarkers with the
required sensitivity and specificity for the detection of fre-
quently occurring cancer types [24].
Over the past decade, system biology especially prote-
omics has been used for the discovery of potential bio-
markers from human fluids including serum [1, 15, 20,
22, 40, 42, 46]. So far, most efforts in proteomics seek
to identify and sequence annotate the proteome by
mass spectrometry analyses of peptides derived through
proteolytic processing of the parent proteome [25, 32,
33, 35]. In such manner, thousands of proteins have
been identified from human serum (www.serumproteo-
me.org). However no validated protein biomarker cur-
rently exists for use in routine clinical practice for lung
cancer early detection, prognosis and the prediction of
treatment response. Proteomic profiling could poten-
tially provide such markers.
One of the challenges from mass spectrometry-based
proteomics is to overcome the analytical bias towards
the most abundant serum proteins, and the complex-
ities of mining the data to a manageable number of bio-
marker proteins that can be analyzed in more depth.
Currently in proteomics research, little attention has
been paid to systematic functional annotation, yet func-
tional annotation is crucial as many proteins have vari-
ants and each functional variant forms may contribute
to its own unique functional activity. It is generally rec-
ognized that sequence annotation alone cannot capture
this vital information, so new strategies are necessary.
So reconciling protein identifications to actual enzyme
activities or functions has been subject to limitations in
proteome separation and assay technologies. To over-
come these inefficiencies in functional annotation, a
top-down approach, starting with function, and ending
with sequence and structural annotation and functional
validation was developed. The PEP technology uses a
modified Two-dimensional Gel Electrophoresis to sep-
arate the proteome, without substantially compromising
function [19]. The isolated proteins are then electro-
eluted from the PEP plate and further refolded, and en-
zyme activities are measured systematically from hundreds
to thousands of fractions depending on the complexity
of the proteome. This method thus provides a new func-
tional dimension to explore the human serum proteome.
Human serum contains thousands of proteins with
abundances spanning eight logs [36]. In the past decade
thousands of proteins have been identified from the hu-
man serum mainly by mass spectrometry technology and
many of them are enzymes supporting catalytic function
within cells (www.serumproteome.org). However, for the
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majority of proteomic applications, antibody-based de-
tection, 2-D gel electrophoresis followed by protein
staining, and quantitative label and label-free LC-MS,
are used to measure protein abundances and carry out
the comparison. Differential gel electrophoresis (DIGE)
is a common method to pair disease sample and con-
trol with two different fluorescence dye staining to
study relative protein up or down regulation, and this
approach has been applied to the identification of po-
tential drug targets or biomarkers [1, 42]. However, the
functional differences between the disease and normal
proteomes can’t be analyzed with approaches solely
reliant on protein abundances, as conformational varia-
tions produce functions, not strictly proportional to the
abundances of the gene derivative polypeptide prod-
ucts. As a result, there is a distinct advantage in charac-
terizing the functions of a proteome.
Many functional assays are very sensitive especially
those based on fluorescence detection, being able to meas-
ure enzyme activities at picogram level [14, 23, 41, 43, 45].
This is significantly more sensitive than the most sensi-
tive detection methods from electrophoretic gels with
silver staining or fluorescence staining, or the general
mass spectrometry methods. Secondly, it is known that
many proteins have post-translational modifications
(PTMs) and splice variants [2], these different forms of
the same gene product may have different functions/
enzyme activities and play very different roles in biol-
ogy. However the important information on the impact
of PTM and protein splicing is lost in the antibody, LC-
MS or gel-based analysis because these platforms can-
not directly measure the functional features of the
proteome. New methods to monitor and compare func-
tional proteomes are therefore desirable.
It is hypothesized that the levels and distributions of
certain enzyme functions in serum could produce
proteomic features and collective profiles which reflect
physiological changes of an individual and can serve
as possible biomarkers or diagnostic parameters. To
achieve such features, a modified 2-D gel electrophor-
esis (2-DE) system can be used; 2-DE being a powerful
tool to separate proteomes based on two orthogonal
parameters, isoelectric point (pI) and molecular weight re-
spectively. Thousands of protein spots can be detected
from a large format 2-D gel. However, the typical 2-D gel
electrophoresis includes the use of reducing reagent to
disrupt the protein disulfide bonds and the use of high
concentration SDS to denature and negatively charge the
proteins for the second dimension separation. In the
current PEP technology, reducing reagent is not used,
keeping the disulfide bonds intact. Furthermore, a
much reduced SDS concentration (0.1 %) was used to
charge the proteins before the second dimension, this is
a 20-fold reduction over the typical SDS treatment.
This modified condition allows the proteins to get
negatively charged but the condition is not strong
enough to destroy the protein tertiary structure. This,
in combination with protein refolding and protein pro-
tectants in the PEP system, allows the efficient recovery
of enzyme activities from the serum proteome after 2-D
gel electrophoresis and protein elution [19]. Our initial
studies using colon and breast cancer patient serum
and normal serum provided strong evidence for a clear
disease signature when the enzyme activities were com-
pared (data not shown). Since most of the functional
proteins or enzymes exist at relatively low level in the
human serum and there is a limited loading capacity on
the 2-DE gel, it is important to enrich the low abundance
proteins before 2-DE and PEP analysis. AlbuVoid™ (Bio-
tech Support Group, Monmouth Junction NJ) has been
shown to effectively enrich low abundance serum proteins
while depleting the Albumin. It was used previously for
pre-treatment of human serum in the PEP technology,
whereby more functional features were observed with
AlbuVoid™ than without (data not shown). Conse-
quently, we adopted AlbuVoid™ in our workflows in this
investigation.
The selection of the activity to be monitored is an im-
portant choice in any functional proteomic investiga-
tion. Previous studies have demonstrated that general
redox enzymes could be detected from beef liver
extract or mouse cochleae tissue, both NADH and
NADPH-dependent oxidases can be detected from a
large number of fractions after 2-D gel separation and
PEP elution [19]. However, the relative enzyme activ-
ities were low because instead of specific substrates,
general enzyme substrates containing all the 20 amino
acids and several sugars were used at relatively low
level; the purpose of this approach was to maximize the
detection of enzyme species using NADH or NADPH
as cofactor. In the current study, a more specific assay
for hexokinase activity was measured, with only two
substrates (glucose and ATP) introduced at optimized
conditions [13]. Hexokinase activity was selected for
several reasons. Foremost is that the products produced
from Hexokinase activity are the first within the glyco-
lytic pathway, a pathway often implicated in cancer de-
velopment [13, 21, 37]. Another reason is that a large
number of functional proteins within and cross-
regulating with the glycolytic pathway could potentially
be monitored by a broad spectrum assay as the one
employed, which already contains low level of endogen-
ous Hexokinase activity. The introduction of exogenous
protein(s) from the PEP samples could potentially
supersede any rate-limiting protein function and en-
hance the hexokinase activity. As such, this assay may
also detect the effect of proteins from other pathways
that cross-interact with the glycolytic pathway.
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Methods
Materials
All the chemicals were purchased from Sigma-Aldrich
(St. Louis, MO). Isoelectric Focusing (IEF) unit that is
capable of running IEF at different length is from Bio-
Rad (PROTEAN IEF Cell). Spectrophotometer Plate
Reader capable of reading 384-well plates with a wide
wavelength selection and fluorescence reading is the
SPECTRAMax Plus from Molecular Devices (Sunnydale,
CA). Semi-Blot unit for protein transfer such as Bio-
Rad’s Trans-Blot SD Semi-Dry Transfer Cell.
Beef liver protein extract preparation
Frozen beef liver tissue purchased from the local super-
market. 5 g of frozen beef liver tissue was chopped up
with a razor blade and homogenized in 2.5 volumes of
phosphate-buffered saline (PBS) using a disposable plas-
tic homogenizer. After spinning at 14,000 g for 15 min,
the supernatant was analyzed for protein concentration
with BCA and frozen at −20 °C in small aliquots for sin-
gle use.
AlbuVoid™ treatment for low abundance serum protein
enrichment
200 mg of AlbuVoid™ beads were used to process 0.8 ml
of human serum (contains about 40 mg total serum pro-
tein). 20 serum samples from normal people or lung
cancer patient were pooled with equal volume (100 μl
each) respectively and separated with AlbuVoid™ accord-
ing to the manufacturer’s instruction. The patient serum
was collected at Wuxi Third People’s Hospital in China
after the approval from the Hospital Ethics Committee
with reference number of 20140102 AlbuVoid™ will not
bind serum albumin, thus this most abundant serum
protein is removed in the flow through fraction and the
rest of serum proteins are enriched on the AlbuVoid™
column. The enriched low abundance serum proteins
were eluted with 0.8 ml elution solution containing 8 M
urea, 2 % CHAPS in 25 mM phosphate buffer, pH 8.0.
The protein concentration was determined by BCA be-
fore 2-D gel electrophoresis.
Isoelectric Focusing (IEF) and 2-D gel electrophoresis
To prepare for the IEF separation, Bio-Lyte Ampholyte
(Bio-Rad #1631112) was added to the elute above for a
final concentration of 0.5 %, rehydrate with 0.4 ml sam-
ple solution with nonlinear pH 3–10 11 cm IPG strip
(Bio-Rad ReadyStrip #1632016) overnight with a total
loading of 1 mg protein/gel. The proteins were separated
using the following setting: 0–7000 voltage gradient for
4 h, Hold at 7000 voltages overnight until running ter-
mination, the IEF was run at room temperature. After
IEF, the IPG strips were taken off the running unit, min-
eral oil from the IPG strip was absorbed with a paper
towel and the IPG strip was transferred to a 12-lane re-
fold tray (Bio-Rad #1654025). 4 ml refolding solution
was added to each lane with the IPG strip and incubated
for 10 min., this step will allow the urea to diffuse out of
the IPG strip and also the refolding of the protein in
the IPG strip, this was followed by incubation with
electrophoresis transfer buffer (Tris-glycine with 0.1 %
SDS), this step will allow the further diffusion of urea
from the IPG strip and most importantly the binding of
SDS to the protein so that all the proteins were nega-
tively charged.
For protein refolding, a proprietary protein refolding
solution was used; the solution contains multiple metal
elements to replace the possible loss of metal ions as en-
zyme cofactors. A redox system to mimic the cell cyto-
plasm was used to assist the protein refolding process.
After protein refolding, the IPG strip was laid down to a
precast 2-D gel (Bio-Rad 10 %-20 % Criterion Gel
#3450107) with the acidic end of the IPG on the left side
of the 2-D gel when facing the gel apparatus. The gel
was operated at 80 volts for 15 min. followed by running
at 120 voltages until the dye front of the gel is 0.5 cm
from the bottom edge of the gel.
Electroelution and protein recovery from the PEP plate
After second dimension gel electrophoresis, the gel was
taken out from the cassette, and laid on top of the PEP
plate which was filled with elution solution. The proteins
were transferred from the gel to the PEP plate for
60 min. at 20 volts using a Semi-Blot apparatus from
Bio-Rad (#1703940.). After protein transfer, the gel was
carefully lifted from the PEP plate, and a multi-channel
pipette transferred the eluted proteins from the PEP
plate to a master plate, containing 50 μl PBS in each
well. About 40–45 μl of solution could be transferred to
the Master Plate for a total volume of 90–95 μl in each
well. In this analysis, 25 μl solution was taken from each
well in the Master Plate and transferred to an enzyme
assay plate to perform the enzyme assay and the
remaining solution was used for mass spectrometry pro-
tein identification.
Hexokinase activity assay
Hexokinase activity can be monitored by a cascade reac-
tion as follows:
Substrates added D‐Glucoseþ ATPf g→Hexokinase
Products D‐Glucose 6‐Phosphateþ ADPf g
D‐Glucose 6‐Phosphate þ ß‐NADP→G‐6‐PDH
6‐Phospho‐D‐Gluconate þ ß‐NADPH
In the final assay solution, glucose was at 216 mM;
MgCl2 at 7.8 mM, ATP at 0.74 mM and NADP at
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1.1 mM. 25 μl of this enzyme assay solution was mixed
with 25 μl of sample from the Master Plate (described
above) and the enzyme activity was monitored by the
340 nm absorbance from the reduction of NADP to
NADPH. The readings at 0, 1 h., 3 h. and overnight were
recorded for both the normal serum and lung cancer
patient serum sample. However, in lieu of purified G-6-
PDH, 0.25 mg/ml beef liver protein was used as the
source of Glucose-6-Phosphate Dehydrogenase (G-6-
PDH). The assay thus reports the additive contributions
of the endogenous Hexokinase activity present in the
beef liver extract, and any exogenous activity from the
presence of test sera protein in the PEP plate, which
may influence the reduction of NAD or NADP (the
reporting signal). In light of the ambiguities that may
arise from such a reporting system, the primary goal of
this investigation was to generate sufficient signal inten-
sities and activity features which could monitored and
compared across samples types within an ‘omics’ con-
text. Therefore, this broader spectrum assay was chosen
over a more narrow spectrum substrate to product turn-
over one, as this broader spectrum assay could poten-
tially detect the activities of downstream glycolytic and
other cross-regulating proteins from the test sera.
Enzyme activity display
Two Microsoft Excel formats were used to display the
enzyme activities. One is to use the 3-D column display
and the other is the heat map.
Protein identification by LC-MS/MS
For fractions with significant hexokinase activity and
also demonstrated qualitative or quantitative differences
between the normal serum and lung cancer patient
serum, sample was recovered from the Master Plate and
treated with 50 μl 20 % cold TCA (Trichloroacetic Acid)
to remove non-protein components and recover the pro-
teins from the fraction. The precipitate was washed
twice with cold acetone to remove the TCA and dried in
a SpeedVac for 60 min. The dried samples were submit-
ted for Mass Spectrometry protein identification. For
MS analysis, the samples were loaded onto a 10 % bis-
Tris NeuPage gel as a gel plug. The gel plug was excised
and proteins in the gel were reduced, carboxymethy-
lated, digest with trypsin using standard protocols. Pep-
tides were extracted, solubilized in 0.1 % trifluoroacetic
acid, 5 % acetonitrile, and analyzed by nanoLC-MS/MS
using a RSLC system (Dionex, Sunnyvale CA) interfaced
with a Velos-LTQ-Orbitrap (ThermoFisher, San Jose,
CA). Samples were loaded onto a self-packed 100 μm×
2 cm trap packed with Magic C18AQ, 5 μm 200 A
(Michrom Bioresources Inc, Aubum, CA) and washed
with Buffer A (0.2 % formic acid) for 5 min with flowrate
of 10 μl/min. The trap was brought in-line with the
homemade analytical column (Magic C18AQ, 3 μm 200
A, 75 μm× 50 cm) and peptides fractionated at 300 nL/
min with a multi-stepped gradient (4 to 15 % Buffer B
(0.16 % formic acid 80 % acetonitrile) in 10 min and
15–35 % B in 55 min, and 30–55 % B in 25 min). Mass
spectrometry data was acquired using a data-dependent
acquisition procedure with a cyclic series of a full scan
acquired in Orbitrap with resolution of 60,000 followed
by MSMS scans (acquired in linear ion trap) of 20 most
intense ions with a repeat count of two and the dy-
namic exclusion duration of 60 s.
The LC-MSMS data was searched against the ensem-
ble human database (most updated) using X!Tandem
through a local version of the Global Proteome Ma-
chine (GPM cyclone, Beavis Informatics Ltd, Winnipeg,
Canada) with carbamidoethyl on cysteine as fixed
modification and oxidation of methionine and trypto-
phan as variable modifications using a 10 ppm precur-
sor ion tolerance and a 0.4 Da fragment ion tolerance.
Results and discussion
For the enzyme activity profiles to produce distinguish-
able features which can be compared, three necessary
components of the method were first validated:
1. Low Abundance Serum Proteins can be enriched
with the AlbuVoid™ beads.
2. 2-DE separation can resolve proteins with
subsequent transfer to PEP multi-well plates, and
3. The Hexokinase assay can monitor refolded proteins
so as to generate a detectable signal over and above
background signal from the activity assay.
Establish low abundance protein enrichment from
human serum
In order to achieve the maximum sensitivity of the PEP
technology, 800 μl of serum (about 40 mg total protein)
was used for the AlbuVoid™ treatment. As can be seen
in Fig. 1, the major serum protein- Albumin, was not
bound to the AlbuVoid™ beads and more low abundance
proteins are detectable. This enrichment process will in-
crease the enzyme assay sensitivity by least 10-fold com-
pared with direct analysis without enrichment.
Establish 2-DE resolution
Before enzyme analysis, a good 2-D gel separation con-
dition needs to be established. For this, we used the
beef liver protein extract to establish the optimum con-
ditions. As can be seen in Fig. 2, at a loading of 400 μg/
gel, most of the beef liver proteins were well separated
under the modified 2-D gel condition (mainly the ex-
clusion of reducing reagents to retain the disulfide
bonds in the protein) and a large number of proteins
were detected by fluorescence staining. For the 2-D gel
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Fig. 1 Enrichment of Low Abundance Proteins from Human Serum. 800 μl pooled serum from normal (N = 20) and lung cancer patient (N = 20)
was used for the enrichment of low abundance proteins with AlbuVoid treatment according to the manufacturer’s instruction. For the comparison,
750 μg protein from untreated serum (normal group) and treated serum (normal group) was loaded onto two 11 cm IPG strips for IEF protein
separation without reducing reagent. For second dimension separation, SDS-PAGE with 10–20 % gradient gel was used, Sypro Ruby was used
for protein staining and detection
Fig. 2 Effective 2-D Gel Separation of Beef Liver Proteins without Reducing Reagent. 400 μg of beef liver protein was loaded on an 11 cm pH
3-10Nonlinear IPG strip, for the second dimension, the proteins were separated in SDS-PAGE with gradient gel of 10–20 %. After fixing, the
proteins were detected by Sypro Ruby staining
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separation of the enriched serum proteins, 1 mg/gel
was used with acceptable resolution (Fig. 1). An un-
stained gel was used to elute proteins directly into a
PEP plate. After elution of the proteins from the 2-D
gel to PEP plate, hexokinase activities were measured
from every well in the 384-well microplate.
Hexokinase activity analysis from 2-D gel-separated
serum proteins
It should be pointed out that the refolding process after
the isoelectric focusing is critical to regain good enzymatic
activity. During IEF, 8 M urea was used to achieve the best
2-D gel separation, however this condition also results in
unfolding of the proteins, therefore after 2-D gel electro-
phoresis, and the proteins need to be refolded. Another
consideration during the refolding process is to replenish
the metal ions lost during gel electrophoresis. It is known
that many enzymes use metal ions as cofactors for their
enzymatic activity; therefore it is important that during
the refolding process, in addition to the protein refolding
system, several metal ions commonly used by enzymes
were added to assist the refolding process. In this step, the
urea from the IPG strip is diffused out and the proteins
would presumably assume the right conformation with
the redox system and metal ions provided. Another im-
portant aspect of the improved gel electrophoresis is the
binding of SDS to the proteins. It is known from previous
studies that many proteins are still active in the presence
of SDS [5], however higher level of SDS could potentially
induce protein inactivation. Therefore a much reduced
SDS concentration was used for the sample treatment be-
fore the second dimension gel electrophoresis. The ration-
ale is that the SDS treatment will just be enough to
negatively charge the protein for an acceptable resolution
but not strong enough to induce significant protein de-
naturation. After electroelution, the eluted proteins from
the PEP plate were transferred to a master plate in which
protein refolding solution was added for the further
refolding of the proteins. As can be seen in Fig. 3, time-
dependent hexokinase activities were detected from a
large number of fractions.
Since this beef liver extract contains all the enzymes in
the glycolytic pathway, any proteins that directly or in-
directly impacts the glycolytic pathway or NADP reduc-
tion (reporting component of the assay), could be
detected in this setting. Therefore the hexokinase
Fig. 3 Time-dependent Measurement of Hexokinase Activity from the PEP Platform. After elution of proteins from the 2-D gel into the 384-well PEP
plate, the eluted proteins were further transferred into a 384-well Master Plate with 50 μl refolding solution. 25 μl of the solution from the Master Plate
was further transferred into a 384-well Enzyme Assay plate, 25 μl of hexokinase assay components were was added to each well, the increase of OD
340 nm by NADP reduction was measured in a spectrophotometer, the OD readings were taken at 0, 60 min. and 120 min., the OD340 nm increase
from 60 min. and 120 min. was calculated by subtracting the value from the 0 min. reading. Top panel: ΔOD after 60 min incubation. Bottom
panel: ΔOD after 120 min incubation
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activity detected in the current assay is not solely the
result of the hexokinase reaction products: Glucose-6-
phosphate & ADP, it could be the combined effect of all
the enzymatic activities monitored by the increase in
spectrophotometric absorbance of NADP reduction. It
is interesting to note that as many as 1/3 of 384 PEP
fractions from the sera, showed various levels of such
activity, suggesting that a large number of proteins from
beef liver might be involved in NADP reduction directly
or indirectly. Another interesting observation from the
hexokinase activity assay on the PEP platform was that
the activities observed were much stronger than the
NADH or NADPH-dependent enzyme assays before
[19], suggesting a more narrow substrate panel is bene-
ficial. The third observation for the hexokinase activity
analysis was the wide distribution of fractions with the
capability of hexokinase activity enhancement, ranging
from molecular size as high as 200 kDa to as low as
5 kDa, and the isoelectric points from 3 to 10, suggest-
ing a wide variety of proteins, not previously annotated
to the glycolytic pathway, may nevertheless be servicing
this pathway directly or indirectly. With an emerging
view that many proteins are multi-functional due to a
continuum of conformational transitions, it will be in-
teresting to identify these proteins and understand how
they contribute to the glycolytic pathway.
Comparison of hexokinase activity from normal serum
and lung cancer patient serum
To demonstrate that hexokinase activity can be moni-
tored from the PEP fractions, the reduction of NADP
was measured at different time points. As can be seen in
Fig. 4, many fractions from the normal serum have time-
dependent hexokinase activities. Similarly, measure-
ments on the serum from lung cancer patients also
showed many fractions with hexokinase activities, and
more interestingly, there are qualitative and quantitative
differences between the normal serum and cancer pa-
tient serum (Figs. 4 and 5).
For a better comparison of the hexokinase activities
between the normal and lung cancer patient sera, a heat
map was constructed using Microsoft Excel (Fig. 6). As
can be seen, a large number of fractions from both the
normal and lung cancer patient serum were found to
have hexokinase activity, even though we may not know
the precise mechanism for up-regulated activity. An-
other interesting observation from Fig. 6 was that there
were many fractions with significant hexokinase activity
differences between the normal and lung cancer group.
For example, in the normal serum, K19 and P10 have
more than 10-fold hexokinase activity than the corre-
sponding fractions in the lung cancer patient serum.
Conversely, from the lung cancer patient serum,
Fig. 4 Time-dependent Hexokinase Activity Analysis from AlbuVoid-enriched Normal Serum. 750 μg AlbuVoid-enriched serum proteins from
normal group was loaded onto an IPG strip and separated by IEF. After further separation by SDS-PAGE, the proteins were eluted into the PEP
plate and hexokinase activities were analyzed from each of the 384 wells. Hexokinase activity was measured by NADP reduction at 340 nm at
0 (a), 60 min (b). and overnight (c) incubation
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fractions A3, D20, E20, F20, O14 and P21 each has
about 10-fold more activities than the corresponding
fractions from the normal group, and those fractions
with enzyme activity showed a time-dependent activity
increase. The above mentioned fractions and many other
fractions will be good candidates to look for potential
biomarkers. Another interesting observation was that
the fractions with hexokinase activity were detected
across a wide range of molecular size and isoelectric
points, suggesting that: 1.) there are many serum pro-
teins that could directly or indirectly impact hexokinase
activities within this assay system, and 2.) there could be
protein variants that show different hexokinase activity
among the fractions. This is the first time that hexoki-
nase activity has been surveyed systematically from a
highly resolved proteome.
Mass spectrometry identification of serum proteins with
glycolytic enzyme activity
For the identification of proteins with demonstrated
time-dependent hexokinase activity from the enzyme
assay plate, the corresponding fractions from the mas-
ter plate (see Materials and Methods for details) were
collected and precipitated by TCA and submitted for
mass spectrometry analysis. It is interesting to note that
the majority of proteins identified with significant se-
quence coverage have not previously been annotated to
the glycolytic pathway; a potential subject for future in-
vestigation. As was shown in Table 1, three known en-
zymes from the glycolytic pathway, GAPDH, PKM and
Enolase, were identified from the MS analysis.
Biological verification with selected protein
It has been reported that many genes from the glycolytic
pathway are up-regulated [30, 39, 48] and repro-
grammed metabolism is considered as a new hallmark of
cancer development [19]. More interestingly, in addition
to their role in mediating tumor growth through metab-
olism reprogramming, some of the metabolites have
been shown to impact the signal transduction pathway
[31], influence the tumor microenvironment or serving
as a metabolic checkpoint for T cell response [8, 9, 21],
all these recent findings suggest that the glycolytic path-
way plays multiple roles in cancer development. As an
example to demonstrate the proteins identified by MS is
indeed enhancing the hexokinase activity, purified
Fig. 5 Time-dependent Hexokinase Activity Analysis from AlbuVoid-enriched Lung Cancer Patient Serum. 750 μg AlbuVoid-enriched serum pro-
teins from lung cancer patient group was loaded onto an IPG strip and separated by IEF. After further separation by SDS-PAGE, the proteins were
eluted into the PEP plate and hexokinase activities were analyzed from each of the 384 wells. Hexokinase activity was measured by NADP reduc-
tion at 340 nm at 0 (a), 60 min (b). and overnight (c) incubation
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GAPDH from a commercial source was spiked into the
hexokinase activity assay system. As can been seen in
Fig. 7, the addition of purified GAPDH enhanced the
hexokinase activity of the system, confirming the find-
ings from the PEP plate and mass spectrometry analysis.
Figure 7 also showed that the hexokinase activity en-
hancement is both GAPDH and hexokinase substrate-
dependent, suggesting that the assay is mainly measuring
the hexokinase product outcome instead of other en-
zymes that indirectly reduce NADP from the system. It
Fig. 6 Comparison of Normal and Lung Cancer Patient Serum Hexokinase Activity Pattern. Hexokinase activities from both normal (upper panel) and
lung cancer (lower panel) patient serum were displayed in a heat-map for comparison and subsequent process for mass spectrometry identification
Table 1 Proteins identified by mass spectrometry after separation with PEP technology and Hexokinase Activity Analysis
Sample number Sample location in PEP plate Tentative protein ID
Sample-1 N19A Plasminogen (PLG)
Sample-2 N7B, N8B Hemopexin (HPX)
Sample-3 N22H, N23H, N22I Complement Component 3 (C3)
Sample-4 N17J, N18J Fatty Acid Synthase (FASN)
Sample-5 N18K, N19K Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)
Sample-6 N10M, N11M Fatty Acid Synthase (FASN)
Sample-7 N15M, N16M Enolase 1 (ENO1)
Sample-8 N1P, N2P, N3P Glyceralde-3-phosphate Dehydrogenase
Sample-9 N10P, N11P Alpha-2-glycoprotein 1 (AZGP1)
Sample-10 C3A Fatty Acid Synthase (FASN)
Sample-11 C9A, C9B Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)
Sample-12 C19D, C20D, C21D Pyruvate Kinase (PKM)
Sample-13 C19E, C20E, C21E Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)
Sample-14 C14O, C14P Fatty Acid Synthase (FASN)
Sample-15 C21P Fatty Acid Synthase (FASN)
*The location of each protein on the 2-D gel was defined by two parameters: the serum group and the location on the 384-plate. 1. The serum group is represented by
the first letter, N represents Normal Serum, and C represents Cancer Serum. For example, N19A represents sample from Normal Serum and the PEP plate well 19A
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will be interesting to further validate the other proteins
identified from the system for their ability to enhance
the hexokinase activity.
Conclusions
Great effort has been made for the discovery and devel-
opment of biomarkers for cancer diagnosis [11, 20, 24,
32, 40], however so far only a handful protein-based
products have been approved with limited value espe-
cially in early cancer detection. One of the challenges
in biomarker discovery has been the lack of disease-
indicating biological features that can show high correl-
ation with disease or disease stages. In cancer studies, it
has long been recognized that cancer has significantly
different metabolic behavior as compared with normal
cells. Otto Warberg was the first to report the increased
metabolic glucose activity in cancer tissue, there has
been many reports linking increased metabolic activities
with cancer development [27, 28, 33, 34, 38, 44, 49]. Re-
cently there has been a surging interest in the develop-
ment of drugs targeting enzymes from the glycolytic
pathway [16–19, 21, 29, 39]. However, it is not clear how
the whole glycolytic pathway and each of the components
in the pathway contribute to the observed increase in
glucose consumption. Using the PEP technology and
the upstream enzyme, hexokinase, it is now possible to
monitor the functions of many components in the
glycolytic pathway and determine which components
differentiate in the increased metabolic activity.
Human serum is very rich in proteins, thousands of
proteins have been identified from human serum and
many of them play important roles in maintaining
homeostasis [7]. However so far no technology is avail-
able to systematically study the function of serum pro-
teins, on the other hand, there is a possibility that the
functions of these serum proteins could be strong indi-
cators in many diseases. With the PEP technology, it is
now possible to analyze the whole enzyme family or
multiple enzyme families simultaneously so that a holis-
tic understanding of the functional proteome of serum is
possible. Using a pool of normal people serum and lung
cancer patient serum, this study demonstrated that a
large number of fractions with hexokinase activity could
be detected, and the hexokinase activity was substrate
and time-dependent. More interestingly, there were
many fractions that showed significant activity difference
between the normal and lung cancer patient, some of
the activities are completely missing from the normal
serum or vice versa. This is important for biomarker dis-
covery and validation because human population could
have very large individual variation in their composition
of the serum [7].
In the current study, the enzyme assay system was de-
signed to detect any rate-limiting enzyme in the glycolytic
pathway because the first enzyme activity in the pathway,
hexokinase, was selected. Therefore, any glycolytic enzymes
downstream of hexokinase could enhance hexokinase kin-
etics by removing downstream products from the system.
This could explain why GAPDH and other enzymes were
Fig. 7 Purified GAPDH Increased Hexokinase Activity. To verify the proteins identified by mass spectrometry were indeed enhance the hexokinase
activity, purified GAPDH was obtained from commercial source and added to the hexokinase activity assay system, and the enzyme activity was
measured by measuring the NADP reduction at 340 nm
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identified from the highly active PEP wells. There are two
important points need to be made from the current
study: 1. that many time-dependent hexokinase activity
fractions were detected from both the normal and lung
cancer sera. This suggests that in human serum, there
are many proteins that directly or indirectly influence
hexokinase activity as measured by this assay. This also
reflects the complexity of hexokinase regulation provid-
ing a potential panel of good biomarkers for diagnosis.
2. There are many hexokinase fractions that showed
more than a 10-fold quantitative difference between the
normal serum and lung cancer serum. This will make
the development of baseline diagnostic monitoring eas-
ier because the detection has wide dynamic response,
necessary for the large variation among the human
population.
It is a little surprising that no gene products of hexoki-
nase were identified from the fractions submitted for
MS analysis. One possible reason is that hexokinase
levels especially the active hexokinase levels in serum
are very low or do not exist, since these activities are not
normally extracellular. Therefore the observed hexoki-
nase activity increase above basal level is likely to be an
enhancement of the endogenous hexokinase activity
from the beef liver extract, which itself contains a back-
ground level of hexokinase activity (shown in Fig. 7). In
any case, the time-dependent and substrate-dependent
increase in NADP reduction (the reporting signal) is at
least an indication of activity enhancement by the pro-
tein(s) isolated from the PEP plate. Another possibility
from the current finding is that the proteins identified
have an alternative function other than their gene-
designated functions. This can be further investigated
in more detail with purified assay components and
substrate.
Finally, we solicit that functional proteomics offers im-
portant insights to complex systems that otherwise
could not be obtained. It is known from previous studies
that human serum contains thousands of proteins [3]
and it is speculated that many of them were leaked from
human tissue, and thus may provide important clues to
the health and status of the human body. Previous stud-
ies have shown that hexokinase activity is associated
with cancer development, and recently an array of re-
ports point to the importance of metabolic pathways in
cancer development [4, 6, 10, 26]. In the current study, a
novel technology - PEP, was used for the systematic ana-
lysis of glycolytic enzymes from human serum. Likewise,
it is interesting to consider all metabolic enzymes as
those that can be monitored and evaluated as possible
biomarkers for staging overall well-being and disease.
Even though only hexokinase activity analysis was re-
ported here, enzyme assays on other families such as
proteases, protein kinases and alkaline phosphatases
were also performed on serum and major differences
were also detected between normal and lung cancer pa-
tient serum (data not shown). So with these new
methods to enrich and resolve functional proteins into
multi-wells that can be profiled molecularly and com-
pared, discoveries of important new lung cancer bio-
markers are anticipated. Furthermore these same
technologies can easily be extended for the development
of biomarkers, drug targets or diagnostic kits for other
types of cancer or disease.
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